Health Policy Commission launches new pharmaceutical oversight and state health planning offices, names directors

The Health Policy Commission announced new offices created by chapters 342 and 343 of the acts of 2024 and named directors for each at its June board meeting.

The commission introduced Matthew Frank as director of the Office of Pharmaceutical Policy and Analysis, which the agency said will examine pharmaceutical spending, increase transparency about pharmacy benefit managers and produce an annual pharmaceutical trends report and survey. "OPA has a clear mandate to investigate this industry through analysis of spending data, increase transparency," the commission said in its implementation overview.

The board also introduced Cara Vidal as director of a new Office of Health Resource Planning, or OHARP. Vidal described the office’s central task as developing a state health resource plan that "must identify anticipated need for healthcare services, the existing resources that the Commonwealth has to meet those needs, and an assessment of whether those needs and those resources are aligned." She told commissioners the first state health resource plan is due Jan. 1, 2027.

Why it matters: the legislation expands the commission’s oversight role on pharmaceutical pricing and market behavior while re-establishing statewide health planning functions intended to identify misalignments between supply and need across Massachusetts. The RPO (Registration of Provider Organizations) program — an HPC data-collection effort — will be integrated into OHARP and the commission plans to implement statutory changes to registration thresholds and reporting requirements in the 2025 cycle.

Background and details: staff said OPA will issue an annual pharmaceutical report focused on access, affordability and spending and will study PBM market practices. The commission introduced Frank by noting his prior work as a senior attorney at the Federal Trade Commission and in the Massachusetts attorney general’s antitrust division, experience staff called directly relevant to PBM investigations.

OHARP’s scope includes conducting focused assessments of supply, distribution and capacity (by service line or geography), holding at least one annual public hearing on its products and using RPO data to inform planning. Vidal said the office will prioritize strategic planning, analytic approaches for distinguishing utilization from need, stakeholder and community engagement, and data gaps that must be filled for robust planning work.

Implementation steps and next actions: staff said the RPO program’s registration threshold will change (the statutory test now counts net patient service revenue from any payer) and that the commission will broaden registrant types (specialty non-acute hospitals, ASCs, urgent care centers, independent labs, freestanding imaging clinics and others) and seek public comment on updated reporting specifications for 2025.

What commissioners asked: members sought clarity on how OHARP will coordinate with existing state plans (DMH, DPH/BSAS and regional efforts) and what levers the office could use to move from study to concrete state action. Vidal said the office aims to aggregate and recomunicate existing work, avoid duplication, and identify opportunities to use existing state mechanisms — for example, the determination of need program and payers’ reimbursement levers — to implement findings.

Next steps: staff will publish RPO guidance and draft reporting specifications for public comment this summer and proceed with regulatory steps to implement the new statutory mandates. The commission did not take a separate formal vote on the office creations during the meeting; implementation work is ongoing.